Clinical trials
Multiple Myeloma trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
79 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Recruiting | 22 |
| Active, not recruiting | 16 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Unknown status | 2 |
| No longer available | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 9 |
| AbbVie | 5 |
| GlaxoSmithKline | 5 |
| European Myeloma Network B.V. | 4 |
| Nordic Myeloma Study Group | 4 |
| Novartis Pharmaceuticals | 4 |
| Oslo University Hospital | 4 |
| Bristol-Myers Squibb | 3 |
| Genentech, Inc. | 3 |
| Janssen Research & Development, LLC | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 79 |
| Recurrence | 14 |
| Neoplasms | 4 |
| Neoplasms, Plasma Cell | 4 |
| Biliary Tract Neoplasms | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Glioma | 1 |
| Hematologic Diseases | 1 |
| Immunoglobulin Light-chain Amyloidosis | 1 |
| Infections | 1 |
Trials
Showing 51 to 75 of 79. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.